![\"\"](\"https:\/\/advancedmedical.tech\/wp-content\/uploads\/2022\/05\/team.png\")
<\/figure><\/div><\/div>\n\n\n\n![\"\"](\"https:\/\/advancedmedical.tech\/wp-content\/uploads\/2022\/05\/doct.png\")
<\/figure><\/div><\/div>\n\n\n\n![\"\"](\"https:\/\/advancedmedical.tech\/wp-content\/uploads\/2022\/05\/hos.png\")
<\/figure><\/div><\/div>\n<\/div>\n\n\n\nNew Cures and Methods<\/strong><\/p>\n\n\n\n Earlier this year a team led by MediChain founder Dr Baker found hints of a radical new way of testing for and predicting Covid-19. Ultimately, an investigation by our Complex Systems Research Division led to a method called Characteristic Leucocyte Differential Count<\/em>. The method was published earlier this year in the Journal Life Research. The cost per test is 10% of that of current tests and because it uses existing blood test infrastructure with no need for extra staff or reagents, it can increase test rates by a factor of 500% overnight.<\/p>\n\n\n\n It’s been featured on BBC Television South Today<\/a> (20 October 2020); Across the country on Heart Radio<\/a> and in the newspapers<\/a> The initial investigation won the global Coronahack<\/a> in London (April 2020), beating hundreds of scientists from around the world including “The brightest minds in the fields of medicine and artificial intelligence . . . 500 Health experts; 500 Data scientists using Real time Covid-19 global health data”<\/em><\/p>\n<\/div>\n\n\n\n The global pandemic continues<\/strong><\/p>\n\n\n\n MediChain were also finalists in the “COVID-19 edition” of the US National Pediatric Medical Device Competition in Washington, DC supported by the US Food and Drug Administration (FDA)<\/p>\n\n\n\n Using this technique and linked with live access to national data using MediChain’s Athena system, it is possible to predict exactly where the new outbreaks will occur and lockdown to prevent them, reducing the period of lockdown and preventing second and future waves of COVID-19.<\/p>\n\n\n\n The UK government has awarded MediChain Ltd. funding from Innovate UK to develop a device that clips onto a smartphone to allow CLDC to be applied anywhere at any time by just about anyone.<\/p>\n\n\n\n On 7 Sept 2020 government representatives told the MediChain team that they receive tens of thousands of applications<\/em> and that accepting MediChain UK\u2019s offering made it One of the top companies at a global level<\/em>.We believe that judges were excited about the impact that we could have on both the national and global economy and public health.<\/p>\n<\/div>\n\n\n\n A far reaching technique<\/strong><\/p>\n\n\n\n As well as being able to form CLDC, the new device developed by MediChain will be able to perform a large number of blood analyses at a low cost anywhere in the world simply by being clipped onto a smartphone. For CLDC it is robust against multiple variants allowing it to detect where other tests fail, as well as allowing it to pick up infection much earlier even than the gold standard RT-PCR test. This is essential in order to stop infections being spread between countries and in populations as pre-symptomatic, potentially infectious, individuals travel having got through RT-PCR testing due to it being too early to be detected. Using CLDC will form a method that prevents this.<\/p>\n\n\n\n The device developed for smartphones by MediChain has a wide range of other applications including; Leukemia detection, Malaria, Sickle Cell Anemia and potential for expansion into Diabetes and liver function.<\/p>\n\n\n\n MediChain and its sister company Hypatia are currently working to develop a pin-prick blood sample test for Covid-19 that anyone can use with a smartphone.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":" SOLUTIONS Transforming lives through smart healthcare solutions. New Cures and Methods Earlier this year a team led by MediChain founder Dr Baker found hints of a radical new way of testing for and predicting Covid-19. Ultimately, an investigation by our Complex Systems Research Division led to a method called Characteristic Leucocyte Differential Count. The method was … <\/p>\n